pharmaceutical coater

ProSolus Seeks Higher Utilization of Transdermal Drug Delivery Technology

ProSolus Seeks Higher Utilization of Transdermal Drug Delivery Technology Parent company, Mission Pharmacal, expands commitment to patch technology with significant investments in manufacturing and commercial team. Transdermal patch production line at ProSolus, Inc. in Miami Juan Mantelle, ProSolus Chief Operating Officer and Chief Scientific Officer Jim Self, ProSolus Commercial Lead Download Press Release MIAMI, Fla.…

LidoFlex

ProSolus, Inc. is proud to announce the upcoming launch of LidoFlex, developed in conjunction with Mission Pharmacal and Richmar. LidoFlex has a 4% Lidocaine concentration, which is the highest concentration available without a prescription. For more information about the product, or if you are a healthcare practitioner interested in LidoFlex, click here.